Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sanofi-Aventis S.A. ADR (NQ: SNY ) 57.59 -0.06 (-0.10%) Streaming Delayed Price Updated: 3:01 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 916,804 Open 57.83 Bid (Size) 57.58 (3) Ask (Size) 57.59 (3) Prev. Close 57.65 Today's Range 57.31 - 57.88 52wk Range 42.63 - 58.97 Shares Outstanding 1,250,690,553 Dividend Yield 3.30% Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Week In Review: Zenas Raises $259 Million In IPO September 28, 2024 It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259... Via Talk Markets Topics Initial Public Offering Exposures Securities Market FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease September 27, 2024 The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating significant reductions in exacerbations and improved lung function in Phase 3... Via Benzinga Exposures Product Safety Performance YTD +15.18% +15.18% 1 Month +2.36% +2.36% 3 Month +16.20% +16.20% 6 Month +19.26% +19.26% 1 Year +7.48% +7.48% More News Read More Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent September 27, 2024 Via Investor's Business Daily Exposures Product Safety Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD September 27, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) September 27, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs September 25, 2024 Via Benzinga Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market September 25, 2024 Via Benzinga Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff September 25, 2024 Via Benzinga Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges September 24, 2024 Via MarketBeat Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences September 23, 2024 Via Benzinga Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval September 23, 2024 Via Benzinga Exposures Product Safety US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices September 20, 2024 Via Benzinga Topics Lawsuit Exposures Financial Legal Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows September 20, 2024 Via Benzinga Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old September 20, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years September 18, 2024 Via Benzinga Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) September 13, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Time To Invest And Or Trade In Bio-Tech Stocks? September 13, 2024 Via Talk Markets Topics ETFs Should You Buy Novavax Stock After This Regulatory Win? September 13, 2024 Via The Motley Fool Biotech Breakout: Stocks for Your Watchlist September 12, 2024 Via MarketBeat Topics ETFs Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease September 11, 2024 Via Benzinga Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial September 11, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Despite its impressive fundamentals, NASDAQ:SNY remains undervalued. September 10, 2024 Via Chartmill FDA Battles Backlog of Drug Factory Inspections Since COVID-19 September 06, 2024 Via Benzinga Exposures Product Safety Why Sanofi Stock Was Robustly Healthy Today September 03, 2024 Via The Motley Fool Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials September 03, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
